Related Experiment Video
Updated: Jul 16, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Recent Developments in the Diagnosis and Treatment of Disseminated and Rare Melanoma with Radiotheranostics
Rüdiger M Exner1, Jason S Lewis1,2,3,4, Lisa Bodei1
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.
Abstract:
Disseminated melanoma, particularly of rare subtypes such as mucosal or uveal melanoma, is a difficult to treat, deadly disease characterized by poor median survival and resistance to a wide range of treatments. Despite new approvals, such as novel immunotherapeutics, there is a significant need for effective therapeutic modalities. Given the successes in the development of targeted radiopharmaceutical diagnostic agents and therapies for other cancers (the so-called theranostics), assessing the efficacy of these strategies in the context of melanoma appears as the next logical step. Here we aim to provide an overview of recent advances in the development of preclinical and clinical melanoma-specific radiopharmaceuticals. Where applicable, we will highlight their relevance in the context of rare subtypes of melanoma.
Insights
Radiopharmaceuticals offer a promising new avenue for treating deadly disseminated melanoma, including rare subtypes. This overview explores advances in melanoma-specific radiopharmaceuticals for diagnosis and therapy.
Area of Science:
- Nuclear medicine and oncology
- Radiopharmaceutical development
- Melanoma research
Background:
- Disseminated melanoma, especially rare mucosal and uveal types, presents significant treatment challenges with poor survival rates.
- Existing treatments, including immunotherapies, have limitations, creating a need for novel therapeutic approaches.
- The success of theranostics in other cancers suggests potential for melanoma.
Purpose of the Study:
- To review recent progress in developing melanoma-specific radiopharmaceuticals.
- To highlight the application of these agents in preclinical and clinical settings.
- To emphasize relevance for rare melanoma subtypes.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of radiopharmaceutical development for melanoma.
- Focus on diagnostic and therapeutic applications.
Main Results:
- Emerging radiopharmaceuticals show potential for targeted diagnosis and therapy in melanoma.
- Advances include agents tailored for specific melanoma characteristics.
- Early data suggests promise for rare melanoma subtypes.
Conclusions:
- Melanoma-specific radiopharmaceuticals represent a logical next step in cancer theranostics.
- These agents hold promise for improving outcomes in disseminated melanoma, including rare subtypes.
- Further research and clinical translation are warranted.
